Treating Patients With Metastatic or Recurrent Cervical Cancer Post Chemotherapy

home / case-based-roundtable-series / treating-patients-with-metastatic-or-recurrent-cervical-cancer-post-chemotherapy

This roundtable series discusses antibody-drug conjugates as therapy for patients with cervical cancer who had progressed on chemotherapy, as discussed by key opinion leaders and participants at virtual live events.

Tisotumab Vedotin Improves Treatment Options in Cervical Cancer

Tisotumab Vedotin Improves Treatment Options in Cervical Cancer

Susan C. Modesitt, MD
July 27th 2023

Susan C. Modesitt, MD, discusses the introduction of antibody drug conjugate tisotumab vedotin to treatment for patients with metastatic cervical cancer.

Second-Line Tisotumab Vedotin Shows Durability in Cervical Cancer

Second-Line Tisotumab Vedotin Shows Durability in Cervical Cancer

Targeted Oncology Staff
September 25th 2023

In the first article of a 2-part series, Shannon N. Westin, MD, MPH, looks at the promising responses to tisotumab vedotin for patients with recurrent or metastatic cervical cancer.